Artemis Investment Management LLP Increases Stake in Repligen Co. (NASDAQ:RGEN)

Artemis Investment Management LLP raised its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 18.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 153,832 shares of the biotechnology company’s stock after purchasing an additional 23,905 shares during the quarter. Artemis Investment Management LLP’s holdings in Repligen were worth $22,143,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of RGEN. UMB Bank n.a. increased its holdings in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. grew its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the 3rd quarter worth $37,000. Quarry LP raised its holdings in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares during the period. Finally, nVerses Capital LLC acquired a new position in shares of Repligen during the 3rd quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $160.51 on Friday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average is $148.36 and its two-hundred day moving average is $144.64.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.23 earnings per share. Analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $185.20.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.